Results 161 to 170 of about 70,073 (274)

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer. [PDF]

Prostate
Kawai T, Maki K, Taguchi S, Fujii Y, Tanaka T, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada D, Yamada Y, Takada T, Nakagawa T, Kume H.   +13 more
europepmc   +1 more source

Editorial Comment on Beyond Total PSA: Clinical Significance of S2,3PSA% in Reducing Unnecessary Prostate Biopsies

International Journal of Urology, Volume 33, Issue 3, March 2026.
Yusuke Goto
wiley   +1 more source

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression. [PDF]

J Clin Invest
Feng T, Xie N, Gao L, Jia Q, Kung SH, Morova T, Li Y, Wang L, Fazli L, Lacombe L, Guillemette C, Lévesque E, Lack NA, Qi J, Han B, Dong X.   +15 more
europepmc   +1 more source

Casticin inhibits AKR1C3 and enhances abiraterone efficacy in castration-resistant prostate cancer. [PDF]

J Nat Med
Piska K, Zubek M, Bucki A, Świtalska M, Koczurkiewicz-Adamczyk P, Władyka B, Kołaczkowski M, Pękala E.   +7 more
europepmc   +1 more source

Heterogeneity in Treatment Effects of Reduced Versus Standard Dose of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. [PDF]

Cancer Med
Fukuokaya W, Mori K, Yanagisawa T, Ito K, Urabe F, Rajwa P, Shariat SF, Kimura T, Hirakawa A.   +8 more
europepmc   +1 more source

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Proceedings of the National Academy of Sciences of the United States of America, 2016
Kanak Raina, Jing Lu, Y. Qian, M. Altieri, D. Gordon, AnnMarie K. Rossi, Jing Wang, Xin Chen, Hanqing Dong, Kam W. Siu, J. Winkler, A. Crew, C. Crews, K. Coleman   +13 more
semanticscholar   +1 more source

KELIM PSA as a Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated with ARPI. [PDF]

J Clin Med
Atalah F, Kuş F, Acarbay A, Karakök A, Alkan O, Nazlı İ, Özilice U, Beşiroğlu M, Gümüş M.   +8 more
europepmc   +1 more source

Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Gao L, Wang B, Liu H, Liu P, Liu L, Han J, Wang X, Dou B, Sun F, Liu W, Wang X, Feng T, Zhao R, Yang X, Chen W, Hu J, Han B.   +16 more
europepmc   +1 more source

Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival.

JAMA Netw Open
Büttner T, Klümper N, Ellinger J, Ritter M, Krausewitz P.   +4 more
europepmc   +1 more source

Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer. [PDF]

Clin Cancer Res
Morris MJ, Flynn J, Zhao B, Anand A, Sjöstrand K, Larson SM, Regazzi AM, Borzillo GV, Park A, Schwartz LH, Heller G.   +10 more
europepmc   +1 more source